Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own2.60% Shs Outstand46.33M Perf Week4.68%
Market Cap1.35B Forward P/E- EPS next Y-3.31 Insider Trans-10.59% Shs Float45.57M Perf Month-8.82%
Income-132.50M PEG- EPS next Q-0.71 Inst Own74.00% Short Float13.54% Perf Quarter-17.86%
Sales21.20M P/S63.51 EPS this Y1.10% Inst Trans2.00% Short Ratio8.21 Perf Half Y-17.79%
Book/sh4.93 P/B5.89 EPS next Y-14.90% ROA-35.10% Target Price44.55 Perf Year27.51%
Cash/sh7.43 P/C3.91 EPS next 5Y- ROE-61.30% 52W Range20.29 - 45.02 Perf YTD-5.43%
Dividend- P/FCF- EPS past 5Y- ROI-48.20% 52W High-35.45% Beta-
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low43.25% ATR1.64
Employees112 Current Ratio14.50 Sales Q/Q138.70% Oper. Margin- RSI (14)48.53 Volatility6.58% 5.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.40% Profit Margin- Rel Volume0.88 Prev Close27.10
ShortableYes LT Debt/Eq0.14 EarningsNov 05 AMC Payout- Avg Volume751.90K Price29.06
Recom2.60 SMA20-2.82% SMA50-4.39% SMA200-14.73% Volume676,586 Change7.23%
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
Oct-01-18 09:00AM  Editas Medicine Grows Scientific Leadership with Two New Appointments GlobeNewswire
Sep-27-18 06:31AM  The Greatest Healthcare Stocks of the 21st Century -- and Some That Probably Will Be Motley Fool
Sep-25-18 01:58PM  Who Owns Most Of Editas Medicine Inc (NASDAQ:EDIT)? Simply Wall St. +6.61%
Sep-21-18 11:23AM  Crispr Appears 'Crispy and Overcooked,' Says Analyst Bloomberg -7.58%
Sep-16-18 08:31AM  Is CRISPR Therapeutics AG a Buy? Motley Fool
Sep-10-18 01:58PM  Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference GlobeNewswire
01:52PM  U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing Reuters
Sep-07-18 08:18AM  Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics Motley Fool
Sep-04-18 11:29AM  Here's Why CRISPR Stocks Rose as Much as 18.7% in August Motley Fool
Aug-31-18 02:27PM  This Start-Up Thinks It Can Tackle One of CRISPR's Biggest Obstacles Motley Fool
Aug-28-18 06:50PM  3 Stocks Your Children Will Brag About Someday Motley Fool
Aug-27-18 04:01PM  Editas Medicine Announces Transition of Chief Medical Officer GlobeNewswire
01:12PM  Gene Editing is a Major Technology to Watch InvestorPlace
07:50AM  Analysis: Positioning to Benefit within Editas Medicine, Alcoa, MaxLinear, Real Goods Solar, NII, and Preformed Line Products Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-24-18 08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-21-18 09:40AM  Edited Transcript of EDIT earnings conference call or presentation 6-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
07:12AM  The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed Motley Fool
Aug-19-18 06:33AM  3 Hot Trends Warren Buffett Is Missing Out On -- But You Don't Have To Motley Fool
Aug-16-18 04:01PM  Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process GlobeNewswire
Aug-13-18 07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-10-18 08:52AM  Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus Zacks
08:45AM  Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock Zacks
Aug-09-18 04:17PM  Editas Prepares for the Commercialization of EDIT-101 Motley Fool
Aug-08-18 01:14PM  Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript Motley Fool
Aug-07-18 08:00AM  Today's Research Reports on Trending Tickers: Editas Medicine and Ligand Pharmaceuticals ACCESSWIRE
Aug-06-18 06:10PM  Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:06PM  Editas: 2Q Earnings Snapshot Associated Press
04:05PM  Editas Medicine Announces Second Quarter 2018 Results and Update GlobeNewswire
04:01PM  Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101 PR Newswire
03:00PM  Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 06:11PM  David Looks Ahead: 1 Massive Trend, 10 Hot Stocks, and 1 Vital Piece of Advice Motley Fool
05:43PM  FoolFest 2018: The Gardner Brothers Look Back -- and Ahead Motley Fool
Jul-30-18 04:02PM  Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results GlobeNewswire
06:50AM  Editas Medicine (EDIT) Enters Oversold Territory Zacks
Jul-28-18 04:20PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
09:03AM  Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer Motley Fool
Jul-25-18 08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
Jul-24-18 04:06PM  Here's Why CRISPR Stocks Are Down as Much as 11.4% Today Motley Fool -8.23%
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -7.12%
02:28PM  CRISPR gene editing can cause risky collateral DNA damage - study Reuters
01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
Jul-10-18 09:37AM  Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far) Motley Fool
Jul-09-18 07:03PM  Cramer's lightning round: Calling bottom in Southwest Air... CNBC Videos
07:20AM  Free Technical Research on Edge Therapeutics and Three More Biotech Equities ACCESSWIRE
Jul-04-18 09:30AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-03-18 11:05PM  A Deep Dive Into The Latest CRISPR Controversy: Heres What You Should Know Motley Fool
Jun-22-18 03:12PM  Editas Medicine Stock History: The Story Behind the CRISPR Gene-Editing Pioneer Motley Fool
09:36AM  Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia Zacks
Jun-21-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within TrustCo Bank Corp NY, Highwoods Properties, Enova International, Editas Medicine, United Insurance, and Cutera New Research Emphasizes Economic Growth GlobeNewswire
Jun-18-18 02:22PM  Is Gene Editing Dangerous? 4 Things You Should Know Motley Fool
09:30AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-16-18 12:01AM  [$$] Gene-Editing Selloff Is Overdone Barrons.com
Jun-13-18 09:00AM  Editas Medicine to Participate in The JMP Securities Life Sciences Conference GlobeNewswire
08:01AM  Should CRISPR Stock Investors Worry About Cancer? Motley Fool
06:02AM  CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic Motley Fool
Jun-12-18 07:01AM  CRISPR-related stocks sink after report that gene-editing technology might cause cancer MarketWatch
Jun-11-18 04:57PM  Here's Why CRISPR Stocks are Getting Rocked Today Motley Fool -7.80%
04:25PM  Gene-Editing Startups Downplay Potential of Cancer Side Effect Bloomberg
04:20PM  Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study Investor's Business Daily
01:56PM  CRISPR stocks tank after research shows edited cells might cause cancer CNBC
Jun-08-18 04:05PM  Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May Motley Fool
03:31AM  FDA Creates Potential Buying Opportunity for CRSP Investopedia
Jun-07-18 08:00AM  3 Stocks That Could Put Apple's Returns to Shame Motley Fool
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks
08:16AM  3 Common Denominators of My 3 Best-Performing Stocks of 2018 So Far Motley Fool
May-31-18 12:29PM  Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Zacks
10:09AM  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA Zacks
08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
08:20AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
May-30-18 03:37PM  What Makes This CRISPR Stock Better Than the Rest? Motley Fool +6.40%
May-18-18 05:00PM  Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates GlobeNewswire -8.24%
May-16-18 07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-15-18 10:04AM  Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? Zacks
May-14-18 07:30AM  [$$] Gene-Editing Pioneers Back Beam Therapeutics The Wall Street Journal
May-11-18 07:20PM  Your Guide to Investing in Gene Editing Motley Fool
08:09AM  3 Growth Stocks for In-the-Know Investors Motley Fool
May-08-18 08:00AM  Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-07-18 06:55AM  Edited Transcript of EDIT earnings conference call or presentation 3-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-05-18 10:16AM  Editas Medicine Starts a "Transformative" Year on a High Note Motley Fool
May-03-18 05:50PM  Editas: 1Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces First Quarter 2018 Results and Update GlobeNewswire
May-02-18 12:19PM  What Diseases Could Gene Editing Cure? Motley Fool
May-01-18 04:56PM  Top Gene-Editing Stocks for Long-Term Investors Motley Fool
Apr-30-18 01:30PM  Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-28-18 10:00AM  3 Stocks That Could Put NVIDIA's Returns to Shame Motley Fool
Apr-27-18 02:35PM  Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge American City Business Journals
Apr-26-18 04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results GlobeNewswire
Apr-23-18 07:06PM  Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like? Simply Wall St.
Apr-20-18 05:12PM  Big Week in Tech for Amazon, Alphabet and Microsoft Yahoo Finance Video
Apr-18-18 10:29AM  Companies with women executives can help you do better in the stock market MarketWatch
Apr-03-18 09:32AM  Oops! CRISPR Concerns Turn Out to be a Big Nothingburger Motley Fool
Mar-28-18 09:00AM  Editas Medicine Names James C. Mullen as Chairman of the Board of Directors GlobeNewswire
Mar-25-18 09:31AM  3 Stocks That Could Double Your Money Motley Fool
Mar-22-18 07:30AM  New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bosley KatrinePresident and CEOOct 01Sale31.0212,000372,2931,240,966Oct 03 04:03 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Option Exercise6.488,00051,8408,000Oct 02 04:02 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Sale32.088,000256,6400Oct 02 04:02 PM
Myer VickeshChief Technology OfficerSep 18Option Exercise11.214,00044,8404,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 18Sale32.194,000128,7600Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Option Exercise0.653,0001,9503,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Sale32.333,00096,9900Sep 19 04:03 PM
Bosley KatrinePresident and CEOSep 04Sale32.3512,000388,2101,252,966Sep 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Option Exercise6.4810,00064,80010,000Sep 05 04:04 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Sale32.2310,000322,3000Sep 05 04:04 PM
Myer VickeshChief Technology OfficerAug 20Option Exercise11.214,00044,8403,600Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 20Sale29.874,000119,4800Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 20Sale30.1712,000362,0081,264,966Aug 22 04:16 PM
Myer VickeshChief Technology OfficerAug 17Option Exercise0.653,0001,9503,000Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Sale29.653,00088,9500Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 01Sale29.558,333246,2531,276,966Aug 03 04:01 PM
Myer VickeshChief Technology OfficerJul 18Option Exercise11.217,00078,4706,150Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 18Sale35.567,000248,8920Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Option Exercise0.657,0004,5504,000Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Sale35.717,000249,9800Jul 19 04:07 PM
Bosley KatrinePresident and CEOJul 02Sale36.298,333302,4411,285,299Jul 05 04:00 PM
Myer VickeshChief Technology OfficerJun 19Option Exercise11.217,00078,4707,000Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 19Sale38.397,000268,7300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Option Exercise0.657,0004,5504,300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Sale38.127,000266,8420Jun 20 04:57 PM
Albright CharlesChief Scientific OfficerJun 13Option Exercise16.5110,000165,10010,000Jun 15 04:16 PM
Albright CharlesChief Scientific OfficerJun 13Sale35.9810,000359,8000Jun 15 04:16 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Option Exercise24.603,00073,8003,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Sale37.103,000111,3000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Option Exercise6.487,00045,3605,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Sale39.287,000274,9700Jun 05 04:08 PM
Bosley KatrinePresident and CEOJun 01Sale37.558,333312,8731,293,632Jun 05 04:06 PM
Albright CharlesChief Scientific OfficerMay 23Option Exercise16.5110,000165,10010,000May 25 04:31 PM
Albright CharlesChief Scientific OfficerMay 23Sale35.0010,000350,0000May 25 04:31 PM
MULLEN JAMES CDirectorMay 18Buy38.0310,000380,25210,000May 22 05:28 PM
Hopfield JessicaDirectorMay 17Buy37.286,700249,7806,700May 21 04:27 PM
Bosley KatrinePresident and CEOMay 01Sale31.958,333266,2391,301,965May 03 05:31 PM
Bosley KatrinePresident and CEOApr 02Sale32.168,333267,9691,310,298Apr 04 04:05 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Option Exercise20.7228,000580,08022,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Sale37.8628,0001,059,9600Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Sale37.656,000225,9000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Sale39.436,000236,5800Mar 20 05:36 PM
Bosley KatrinePresident and CEOMar 09Sale45.009,134411,0301,318,631Mar 13 08:45 AM
Bosley KatrinePresident and CEOMar 01Sale35.728,333297,6931,327,765Mar 05 04:52 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Sale35.326,000211,9200Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale34.616,000207,6600Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Sale32.716,000196,2600Feb 16 04:04 PM
Bosley KatrinePresident and CEOFeb 01Sale36.188,333301,4511,336,098Feb 05 06:05 PM
Bosley KatrinePresident and CEOJan 30Sale40.0510,000400,5201,344,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 29Sale37.5310,000375,3401,354,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 23Sale35.283,338117,7651,364,431Jan 25 04:11 PM
Bosley KatrinePresident and CEOJan 03Sale35.046,662233,4161,367,769Jan 04 04:09 PM
Bosley KatrinePresident and CEOJan 02Sale33.448,333278,6371,374,431Jan 04 04:09 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Option Exercise3.234,64915,0164,649Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 19Sale25.064,649116,5100Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 18Sale24.685,000123,4090Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Option Exercise3.235,00016,1505,000Dec 19 04:38 PM
Hack Andrew A. F.Chief Financial OfficerDec 15Sale24.315,000121,5460Dec 19 04:38 PM
Bosley KatrinePresident and CEODec 01Sale29.588,333246,5221,382,764Dec 05 06:08 AM
Hack Andrew A. F.Chief Financial OfficerNov 20Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 20Sale25.355,000126,7320Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Option Exercise3.235,00016,1505,000Nov 21 04:04 PM
Hack Andrew A. F.Chief Financial OfficerNov 17Sale24.815,000124,0730Nov 21 04:04 PM
Bosley KatrinePresident and CEONov 01Sale23.648,333196,9661,391,097Nov 03 04:48 PM